“Serum Nutrient Levels as Risk Factors for Neovascular AMD”, in Annual Meeting, Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, FL, 2005.
, “Association between C-Reactive Protein and Macular Degeneration”, JAMA, vol. 291, pp. 704-710, 2004.
, “Change in Area of Geographic Atrophy in the Age-Related Eye Disease Study: AREDS Report Number 26”, Arch Ophthalmol, vol. 127, pp. 1168-1174, 2009.
, “C-Reactive Protein and Homocysteine are Associated With Dietary and Behavioral Risk Factors for Age-Related Macular Degeneration”, Nutrition, vol. 22, pp. 441-443, 2006.
, “Genome-Wide Association Identifies SKIV2L and MYRIP as Protective Factors for Age-Related Macular Degeneration”, Genes Immun, vol. 11, pp. 609-621, 2010.
, “Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus Type 1”, AIDS Res HumRetroviruses, vol. 16, pp. 2019-35, 2000.
, “Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.”, AIDS Res Hum Retroviruses, vol. 16, no. 18, pp. 2019-35, 2000.
, “Mitochondrial DNA Variants of Respiratory Complex I That Uniquely Characterize Haplogroup T2 Are Associated with Increased Risk of Age-Related Macular Degeneration”, PLoS One, vol. 4, p. e5508, 2009.
, “Natural History of Drusenoid Pigment Epithelial Detachment in Age-Related Macular Degeneration: Age-Related Eye Disease Study Report No. 28”, Ophthalmology, vol. 117, pp. 489-499, 2010.
, “Progression of Geographic Atrophy and Genotype in Age-Related Macular Degeneration”, Ophthalmology, vol. 117, pp. 1554-1559, 1559 e1551, 2010.
, “Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers”, J Infec Dis, vol. 183, pp. 1343-52, 2001.
“Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.”, J Infect Dis, vol. 183, no. 9, pp. 1343-52, 2001.
, “Secondary Analyses of the Effects of Lutein/Zeaxanthin on Age-Related Macular Degeneration Progression: AREDS 2 Report Number 3”, JAMA Ophthalmol, vol. 132, pp. 142-149, 2014.
,